Prosigna identified a large high-clinical-risk subgroup with minimal chemotherapy benefit, estimated to avert at most two recurrences per 100 patients treated. Enrollment broadened prior assay use by ...
The US Food and Drug Administration (FDA) on Monday finalized guidance to pharmaceutical and biotech sponsors looking for more advice on when non-inferiority studies demonstrating effectiveness of an ...
The European Medicines Agency (EMA) is proposing a new guideline on sponsors’ use of non-inferiority designs to assess the safety and effectiveness of new drugs in clinical trials. The proposal aims ...
Correspondence to Professor Steven M McPhail, Australian Centre for Health Services Innovation, Queensland University of Technology, Kelvin Grove, QLD 4059, Australia; steven.mcphail{at}qut.edu.au ...
FOLFOX4/XELOX in stage II–III colon cancer: Efficacy results of the Italian three or six colon adjuvant (TOSCA) trial. This is an ASCO Meeting Abstract from the 2017 ASCO Annual Meeting I. This ...
Kodiak Sciences Inc said on Wednesday results from a mid-to-late stage trial failed to show non-inferiority of its experimental eye drug KSI-301 compared to Regeneron Pharmaceuticals' Eylea. The views ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results